These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 1856148)

  • 21. Amikacin pharmacokinetics: wide interpatient variation in 98 patients.
    Zaske DE; Strate RG; Kohls PR
    J Clin Pharmacol; 1991 Feb; 31(2):158-63. PubMed ID: 2010561
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Randomized clinical trial comparing ceftriaxone/amikacin versus ceftazidime/amikacin as initial therapy of febrile episodes in neutropenic patients.
    Yataganas X; Rombos Y; Vayopoulos G; Meletis J; Avlami A
    Chemotherapy; 1991; 37(5):376-81. PubMed ID: 1804599
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Single daily dose amikacin in paediatric patients with severe gram-negative infections.
    Trujillo H; Robledo J; Robledo C; Espinal D; Garces G; Mejia J; Restrepo C; Restrepo F; Mejia de Rodriguez GI; Tamayo de Guitierrez MC
    J Antimicrob Chemother; 1991 May; 27 Suppl C():141-7. PubMed ID: 1856143
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Continuous infusion versus intermittent administration of ceftazidime in critically ill patients with suspected gram-negative infections.
    Benko AS; Cappelletty DM; Kruse JA; Rybak MJ
    Antimicrob Agents Chemother; 1996 Mar; 40(3):691-5. PubMed ID: 8851594
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A prospective, controlled, randomized, non-blind, comparative study of the efficacy and safety of a once daily high dose of ceftriaxone plus ciprofloxacin versus thrice daily ceftazidime plus amikacin in empirical therapy for febrile neutropenic patients.
    Metallidis S; Kollaras P; Giannakakis T; Seitanidis B; Kordosis T; Nikolaidis J; Hatzitolios A; Nikolaidis P
    Eur J Intern Med; 2008 Dec; 19(8):619-24. PubMed ID: 19046729
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of amikacin dosing schedule in critically ill elderly patients with different stages of renal dysfunction.
    Ghaffari S; Hadi AM; Najmeddin F; Shahrami B; Rouini MR; Najafi A; Mojtahedzadeh M
    Eur J Hosp Pharm; 2022 Mar; 29(e1):e67-e71. PubMed ID: 34588225
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prospective randomized study of once-daily versus twice-daily amikacin regimens in patients with systemic infections.
    Karachalios GN; Houpas P; Tziviskou E; Papalimneou V; Georgiou A; Karachaliou I; Halkiadaki D
    Int J Clin Pharmacol Ther; 1998 Oct; 36(10):561-4. PubMed ID: 9799062
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Multicenter quality control study of amikacin assay for monitoring once-daily dosing regimens. International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer.
    Blaser J; König C; Fatio R; Follath F; Cometta A; Glauser M
    Ther Drug Monit; 1995 Apr; 17(2):133-6. PubMed ID: 7624900
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A study of amikacin given once versus twice daily in serious infections.
    Maller R; Isaksson B; Nilsson L; Sörén L
    J Antimicrob Chemother; 1988 Jul; 22(1):75-9. PubMed ID: 3170393
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Population Pharmacokinetic Study of the Suitability of Standard Dosing Regimens of Amikacin in Critically Ill Patients with Open-Abdomen and Negative-Pressure Wound Therapy.
    Carrié C; Delzor F; Roure S; Dubuisson V; Petit L; Molimard M; Breilh D; Biais M
    Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 31964795
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Amikacin dosing in neonates: evaluation of a dosing chart based on population pharmacokinetic data.
    Petersen PO; Wells TG; Kearns GL
    Dev Pharmacol Ther; 1991; 16(4):203-11. PubMed ID: 1782838
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Once daily ceftriaxone plus amikacin vs. three times daily ceftazidime plus amikacin for treatment of febrile neutropenic children with cancer. Writing Committee for the International Collaboration on Antimicrobial Treatment of Febrile Neutropenia in Children.
    Charnas R; Lüthi AR; Ruch W
    Pediatr Infect Dis J; 1997 Apr; 16(4):346-53. PubMed ID: 9109134
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Population pharmacokinetics of single-dose amikacin in critically ill patients with suspected ventilator-associated pneumonia.
    Burdet C; Pajot O; Couffignal C; Armand-Lefèvre L; Foucrier A; Laouénan C; Wolff M; Massias L; Mentré F
    Eur J Clin Pharmacol; 2015 Jan; 71(1):75-83. PubMed ID: 25327505
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Optimizing Amikacin Dosage in Pediatrics Based on Population Pharmacokinetic/Pharmacodynamic Modeling.
    Alqahtani S; Abouelkheir M; Alsultan A; Elsharawy Y; Alkoraishi A; Osman R; Mansy W
    Paediatr Drugs; 2018 Jun; 20(3):265-272. PubMed ID: 29569124
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Amikacin Initial Dose in Critically Ill Patients: a Nonparametric Approach To Optimize
    Boidin C; Bourguignon L; Cohen S; Roger C; Lefrant JY; Roberts JA; Allaouchiche B; Lepape A; Friggeri A; Goutelle S
    Antimicrob Agents Chemother; 2019 Nov; 63(11):. PubMed ID: 31481443
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Multicenter, randomized trial of ciprofloxacin plus azlocillin versus ceftazidime plus amikacin for empiric treatment of febrile neutropenic patients.
    Flaherty JP; Waitley D; Edlin B; George D; Arnow P; O'Keefe P; Weinstein RA
    Am J Med; 1989 Nov; 87(5A):278S-282S. PubMed ID: 2686429
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Relationship between hemodynamic and vital support measures and pharmacokinetic variability of amikacin in critically ill patients with sepsis.
    Lugo G; Castañeda-Hernández G
    Crit Care Med; 1997 May; 25(5):806-11. PubMed ID: 9187600
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Steady-State Ceftazidime-Avibactam Serum Concentrations and Dosing Recommendations in a Critically Ill Patient Being Treated for Pseudomonas aeruginosa Pneumonia and Undergoing Continuous Venovenous Hemodiafiltration.
    Soukup P; Faust AC; Edpuganti V; Putnam WC; McKinnell JA
    Pharmacotherapy; 2019 Dec; 39(12):1216-1222. PubMed ID: 31596506
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetic and Pharmacodynamic Analysis of Ceftazidime/Avibactam in Critically Ill Patients.
    Stein GE; Smith CL; Scharmen A; Kidd JM; Cooper C; Kuti J; Mitra S; Nicolau DP; Havlichek DH
    Surg Infect (Larchmt); 2019 Jan; 20(1):55-61. PubMed ID: 30351195
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A study of once-daily amikacin with low peak target concentrations in intensive care unit patients: pharmacokinetics and associated outcomes.
    Bacopoulou F; Markantonis SL; Pavlou E; Adamidou M
    J Crit Care; 2003 Jun; 18(2):107-13. PubMed ID: 12800120
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.